UK Biobank Launches Largest Proteomics Study to Transform Disease Research

The groundbreaking project will analyze 5,400 proteins in 600,000 samples, offering unprecedented insights into disease mechanisms and early detection.

The UK Biobank study will measure 5,400 proteins in 600,000 blood samples, including follow-up samples from 100,000 participants over 15 years.
This initiative aims to revolutionize diagnostics, prognostics, and drug discovery by integrating proteomic, genetic, and imaging data.
Pilot data from 2023 linked over 14,000 genetic variants to protein changes, uncovering potential biomarkers for diseases like cancer, dementia, and autoimmune conditions.
The study is backed by 14 pharmaceutical companies, with initial data releases expected in 2026 and the full dataset available by 2027.
Researchers anticipate the findings will enable earlier disease detection, personalized treatments, and the repurposing of existing drugs for new conditions.